[go: up one dir, main page]

PE20090877A1 - 1,2,4-triazoles trisustituidos - Google Patents

1,2,4-triazoles trisustituidos

Info

Publication number
PE20090877A1
PE20090877A1 PE2008001799A PE2008001799A PE20090877A1 PE 20090877 A1 PE20090877 A1 PE 20090877A1 PE 2008001799 A PE2008001799 A PE 2008001799A PE 2008001799 A PE2008001799 A PE 2008001799A PE 20090877 A1 PE20090877 A1 PE 20090877A1
Authority
PE
Peru
Prior art keywords
compounds
phenylamine
butan
triazol
ethylamine
Prior art date
Application number
PE2008001799A
Other languages
English (en)
Inventor
Johannes Wilhelmus John F Thuring
Bruyn Marcel Frans Leopold De
Wei Zhuang
Anne Simone Josephine Lesage
Theodorus Dinklo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20090877A1 publication Critical patent/PE20090877A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1-ALQUIL-3-ANILINA-5-ARILTRIAZOLES DE FORMULA (I) DONDE R1 ES -CH3, ETILAMINO O METOXIETILAMINO; R2 ES H O -CH3; R3 ES F, Cl, -CF3 O -CH3; R4 ES H O F; R5 ES H, F, Cl O -OCH3; R6 ES ALQUILO(C1-C3). SON COMPUESTOS PREFERIDOS: (S)-1-[3-(3,4-DIFLUOR-FENILAMINO)-5-(2,6-DIMETIL-PIRIDIN-4-IL)-[1,2,4]TRIAZOL-1-IL]-BUTAN-2-OL, (R)-1-[3-(3-CLORO-FENILAMINO)-5-(2-ETILAMINO-PIRIDIN-4-IL)-[1,2,4]TRIAZOL-1-IL]-BUTAN-2-OL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES ALOSTERICOS SELECTIVOS DE RECEPTORES ACETILCOLINA ALFA7 NICOTINICOS SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE HUNTINGTON
PE2008001799A 2007-10-18 2008-10-17 1,2,4-triazoles trisustituidos PE20090877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118825 2007-10-18

Publications (1)

Publication Number Publication Date
PE20090877A1 true PE20090877A1 (es) 2009-07-02

Family

ID=38754647

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001799A PE20090877A1 (es) 2007-10-18 2008-10-17 1,2,4-triazoles trisustituidos

Country Status (16)

Country Link
US (1) US8440701B2 (es)
EP (1) EP2212309B1 (es)
JP (1) JP2011500625A (es)
CN (1) CN101827836B (es)
AR (1) AR070661A1 (es)
AU (1) AU2008313776B2 (es)
CA (1) CA2697974C (es)
CL (1) CL2008003066A1 (es)
ES (1) ES2424023T3 (es)
IL (1) IL205101A (es)
MX (1) MX2010004177A (es)
PA (1) PA8799801A1 (es)
PE (1) PE20090877A1 (es)
RU (1) RU2474579C2 (es)
TW (1) TWI438198B (es)
WO (1) WO2009050186A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97257C2 (en) * 2006-10-19 2012-01-25 Такеда Фармасьютикал Компани Лимитед Indole derivatives
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CA2714662C (en) * 2008-03-19 2016-05-10 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
EA018187B1 (ru) * 2008-05-09 2013-06-28 Янссен Фармацевтика Нв Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
MY161236A (en) 2011-02-25 2017-04-14 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
DE3773746D1 (en) 1986-05-07 1991-11-21 Fisons Plc Pyrazole.
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
US4761422A (en) 1986-11-20 1988-08-02 Lusofarmaco Istituto Lusofarmaco D'italia Spa (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO1998028282A2 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK1070708T3 (da) 1999-07-21 2004-05-10 Hoffmann La Roche Triazolderivater
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
WO2001064674A1 (en) 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2001074793A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2002024200A1 (en) 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ES2266313T3 (es) 2000-12-22 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados de triazolodiamina sustituidos como inhibidores de la quinasa.
MXPA04001399A (es) 2001-08-13 2004-05-27 Janssen Pharmaceutica Nv Derivados de tiazolilo 2-amino-4,5-trisustituidos.
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
WO2003062215A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
DE60310548T2 (de) 2002-05-07 2007-05-10 Neurosearch A/S Diazabicyclische biarylderivate
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
CA2523852A1 (en) 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
CA2525547C (en) 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
ATE439837T1 (de) * 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
EP1648876A1 (en) 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP5116092B2 (ja) * 2004-09-17 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なジアミノトリアゾール化合物
CA2584752A1 (en) * 2004-10-21 2006-05-04 Vertex Pharmaceuticals Incorporated Triazoles useful as inhibitors of protein kinases
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US7645778B2 (en) * 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
EA015034B1 (ru) 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CA2714662C (en) * 2008-03-19 2016-05-10 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
BRPI0910585A2 (pt) 2008-04-17 2015-09-22 Glaxo Group Ltd indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7
EA018187B1 (ru) * 2008-05-09 2013-06-28 Янссен Фармацевтика Нв Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
BR112012005960A2 (pt) * 2009-09-17 2016-03-15 Janssen Pharmaceutica Nv n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
MY161236A (en) 2011-02-25 2017-04-14 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr

Also Published As

Publication number Publication date
CL2008003066A1 (es) 2009-10-16
ES2424023T3 (es) 2013-09-26
TW200934769A (en) 2009-08-16
US20100216846A1 (en) 2010-08-26
RU2474579C2 (ru) 2013-02-10
RU2010119459A (ru) 2011-11-27
CN101827836A (zh) 2010-09-08
CN101827836B (zh) 2014-02-19
CA2697974C (en) 2015-06-30
AR070661A1 (es) 2010-04-28
AU2008313776A1 (en) 2009-04-23
IL205101A0 (en) 2010-11-30
EP2212309A1 (en) 2010-08-04
WO2009050186A1 (en) 2009-04-23
HK1146281A1 (en) 2011-05-27
AU2008313776B2 (en) 2013-12-05
IL205101A (en) 2015-02-26
MX2010004177A (es) 2010-05-03
TWI438198B (zh) 2014-05-21
PA8799801A1 (es) 2009-05-15
CA2697974A1 (en) 2009-04-23
US8440701B2 (en) 2013-05-14
JP2011500625A (ja) 2011-01-06
EP2212309B1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20081532A1 (es) Compuestos novedosos
PE20141375A1 (es) Activadores de glucoquinasa
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20090641A1 (es) Amidas heterociclicas
PE20081884A1 (es) Inhibidores heterociclicos de la aspartil proteasa
PE20141943A1 (es) Antagonistas de trpv4
PE20142099A1 (es) Derivados de sulfonamida
PE20131118A1 (es) Derivados de heteroarilpiperidina y piperazina como fungicidas
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20091816A1 (es) Inhibidores de bace
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20090328A1 (es) Derivados de oxadiazol como moduladores de los receptores metabotropicos de glutamato
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20091618A1 (es) 1,2,4-triazoles trisustituidos

Legal Events

Date Code Title Description
FG Grant, registration